PURPOSE: Advanced cancers of the bile duct and gallbladder carry an ominous prognosis. Rebeccamycin analogue (RA) is a novel antitumor antibiotic where phase I trials suggested clinical efficacy in patients with biliary cancers. METHODS: The primary objective was to determine the response rate to RA in patients with advanced gallbladder and bile duct tumors. Secondary endpoints were survival and pharmacokinetic characterization. RA was given at a dose 165 mg/(m(2) day) x 5 days every 3 weeks. RESULTS: Forty-six patients were enrolled. Nine patients were removed from study before their first planned imaging study for response. Two patients had partial responses and 16 had stable disease. On an intent-to-treat analysis the median survival was 6.3 months. A >20% drop in CA19.9 was seen in 43% of patients with initial high levels. Grade 4 neutropenia and thrombocytopenia were seen in 35 and 5% of patients, respectively. Febrile neutropenia occurred in 16% of patients. The pharmacokinetic profile of this trial closely resembles those of prior phase I trials. Measured biliary concentrations of RA were as much as 100x greater than simultaneous plasma concentration. CONCLUSION: Although RA has a response rate of 5% in advanced biliary cancers, it is associated with significant numbers of patients experiencing prolonged stable disease. Biliary concentrations of RA are significantly greater than plasma concentrations.
PURPOSE: Advanced cancers of the bile duct and gallbladder carry an ominous prognosis. Rebeccamycin analogue (RA) is a novel antitumor antibiotic where phase I trials suggested clinical efficacy in patients with biliary cancers. METHODS: The primary objective was to determine the response rate to RA in patients with advanced gallbladder and bile duct tumors. Secondary endpoints were survival and pharmacokinetic characterization. RA was given at a dose 165 mg/(m(2) day) x 5 days every 3 weeks. RESULTS: Forty-six patients were enrolled. Nine patients were removed from study before their first planned imaging study for response. Two patients had partial responses and 16 had stable disease. On an intent-to-treat analysis the median survival was 6.3 months. A >20% drop in CA19.9 was seen in 43% of patients with initial high levels. Grade 4 neutropenia and thrombocytopenia were seen in 35 and 5% of patients, respectively. Febrile neutropenia occurred in 16% of patients. The pharmacokinetic profile of this trial closely resembles those of prior phase I trials. Measured biliary concentrations of RA were as much as 100x greater than simultaneous plasma concentration. CONCLUSION: Although RA has a response rate of 5% in advanced biliary cancers, it is associated with significant numbers of patients experiencing prolonged stable disease. Biliary concentrations of RA are significantly greater than plasma concentrations.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A Dowlati; C L Hoppel; S T Ingalls; S Majka; X Li; N Sedransk; T Spiro; S L Gerson; P Ivy; S C Remick Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: P Papakostas; C Kouroussis; N Androulakis; G Samelis; G Aravantinos; K Kalbakis; E Sarra; J Souglakos; S Kakolyris; V Georgoulias Journal: Eur J Cancer Date: 2001-10 Impact factor: 9.162
Authors: Cathy Eng; Ramesh K Ramanathan; Ramesh K Ramathan; Michael K Wong; Scot C Remick; Lanting Dai; Kurombi T Wade-Oliver; Sridhar Mani; Hedy L Kindler Journal: Am J Clin Oncol Date: 2004-12 Impact factor: 2.339
Authors: William P Daines; Vandana Rajagopalan; Michael L Grossbard; Peter Kozuch Journal: Oncology (Williston Park) Date: 2004-07 Impact factor: 2.990
Authors: Charles J Nock; Joanna M Brell; Joseph A Bokar; Matthew M Cooney; Brenda Cooper; Joseph Gibbons; Smitha Krishnamurthi; Sudhir Manda; Panayiotis Savvides; Scot C Remick; Percy Ivy; Afshin Dowlati Journal: Invest New Drugs Date: 2009-09-23 Impact factor: 3.850
Authors: Peter J Goldman; Katherine S Ryan; Michael J Hamill; Annaleise R Howard-Jones; Christopher T Walsh; Sean J Elliott; Catherine L Drennan Journal: Chem Biol Date: 2012-07-27